Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974905 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL13359041 | 0.87 | MAPT (0.66) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL29151956 | 0.86 | TTR (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL29151961 | 0.86 | TTR (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL498633 | 0.84 | ESR1 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL498634 | 0.84 | ESR1 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3970919 | 0.84 | TNFRSF1A (0.65) | — | |
| SCHEMBL30631203 | 0.84 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL498894 | 0.84 | MAOB (0.65) | CXCL12 | |
| SCHEMBL498895 | 0.84 | MAOB (0.65) | CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113230240-B | 1,3-diphenylprop-2-en-1-one derivative and application thereof | 广州医科大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-113230240-A | 1, 3-diphenylprop-2-en-1-one derivative and application thereof | 广州医科大学 | 2021-08-10 | — | — | CN | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | CYP1A2 1583/4885CYP3A4 3088/4885CYP2D6 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.